Stopping
cancer requires understanding the patient’s tumor expression
Stopping cancer requires
new targets
Stopping
cancer requires new therapies and new combinations
Stopping cancer
is our mission
DKN-01 –
an anti-DKK1
antibody
A new targeted therapy in development for cancer patients with DKK1 expressing tumors
learn more
News releases
Join our team
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
